CRLX101: Updated Phase I data

Updated data from 24 patients in the dose-escalation Phase I portion of an ongoing, open-label, U.S. Phase I/IIa trial showed that 5 patients treated with CRLX101 who had previously relapsed and progressed on multiple lines of therapy remained free from disease progression for >6 months. The MTD was 15 mg/m 2 CRLX101 every other week. Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Berlin. ...